Introduction: Exenatide is gradually released from exenatide once weekly (QW)
INTRODUCTION
Type 2 diabetes (T2D) is a chronic disease necessitating long-term, individualized treatment. Challenges associated with some treatments include weight gain, risk of hypoglycemia, gastrointestinal side effects, and rapid loss of glycemic control [1] [2] [3] . Other factors considered by physicians and patients may include mode of administration, frequency of dosing, and initial timing of therapeutic response, particularly for patients with symptomatic hyperglycemia.
The glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide improves glycemic control and reduces weight, with a low risk of hypoglycemia when taken without concomitant sulfonylureas or insulin, but an increased risk of gastrointestinal events [4] . The once weekly (QW) formulation has demonstrated sustained glycemic control and is dosed infrequently [5] , but the initial rate of therapeutic response has been questioned. 
METHODS
Details of the DURATION-5 (ClinicalTrials.gov identifier: NCT00877890) study design were previously published [11] . Briefly, patients with T2D aged C18 years who were treated for C2 months with diet and exercise alone or with a stable, maximally effective regimen of metformin, sulfonylurea, thiazolidinedione, or a combination of these medications and had a glycated hemoglobin (HbA1c) of 7.1-11.0%, fasting plasma glucose (FPG) \280 mg/dL, and 
RESULTS
Baseline demographics and characteristics were generally well-matched between patients in the ITT (n = 129) and PK-evaluable (n = 72) populations, with small differences in age and race (Table 1 ). In the ITT population, 20 patients (15.5%) treated with exenatide QW withdrew during the study (withdrawal of consent, n = 6; AE, n = 6; lost to follow-up, n = 5; loss of glucose control, n = 3) [11] . Exenatide QW was generally well tolerated, with no discontinuations due to nausea or vomiting [11] . Reductions in FPG and HbA1c were similar among patients with and without nausea although weight loss was numerically greater in patients with nausea (difference of 0.7 kg; ITT population; Table 2 ). Nausea and vomiting decreased over the 24-week treatment period (Fig. 2) . The incidence of nausea peaked at week 6 (7.2%) and that of vomiting at week 8 (2.4%), declining thereafter. Data are mean ± standard deviation unless otherwise noted BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, ITT intent-to-treat, PK pharmacokinetic, QW once weekly a One patient had missing baseline HbA1c; ITT population, n = 128; PK-evaluable population, n = 71 most rapidly (at week 4-the earliest time point measured), as the PK threshold for FPG lowering (*50 pg/mL) [12] is typically reached at 2 weeks [9] . A recent post hoc analysis of pooled data from 12 clinical trials reported significant reductions in FPG, HbA1c, body weight, and Fig. 1 Initial reductions in FPG, HbA1c, and body weight occurred before steady state exenatide concentrations were reached. Geometric mean ± SE exenatide concentrations (PK-evaluable population) and LS mean ± SE changes from baseline (ITT population) in FPG, HbA1c, and body weight. The PK threshold for FPG lowering with exenatide QW (*50 pg/mL) is typically reached at *2 weeks [9] . FPG fasting plasma glucose, HbA1c glycated hemoglobin, ITT intent-to-treat, LS least-squares, PK pharmacokinetic, SE standard error Table 2 Changes from baseline in FPG, HbA1c, and body weight in patients treated with exenatide QW with or without nausea (intent-to-treat population) supporting an early onset of action [13] . In this study, the time course of HbA1c change, which is more gradual than FPG because it depends on red blood cell turnover, was near maximal 14 weeks after initiation of exenatide QW. Changes in weight also occurred more slowly than effects on FPG, as the physiology of weight loss is more gradual than that of FPG gastrointestinal tolerability compared with rapid dose escalation [14] . Similarly, pooled analyses of randomized controlled trials found that gastrointestinal AEs occurred less frequently with exenatide QW (providing continuous exenatide exposure) compared with exenatide BID (providing intermittent exenatide exposure), and decreased over time [15, 16] . These analyses further support the notion that the gradual increase in exenatide concentration through the microspheres enhances gastrointestinal tolerability.
DISCUSSION
While some physicians and patients seek to avoid gastrointestinal AEs, others may believe that nausea indicates response to therapy. Our subanalysis results counter this belief, showing 
CONCLUSIONS
Although exenatide-containing microspheres deliver exenatide via a gradual release mechanism, exenatide QW resulted in prompt treatment responses once the activity threshold was reached, which occurred weeks before steady state exenatide concentrations were attained. Near-maximal improvements in FPG and clinically relevant reductions in HbA1c (-0.6%) occurred by week 4, followed by weight loss. The occurrence of nausea and vomiting declined over time, with tolerance developing as exenatide reached steady state concentrations.
